MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
Key Details
- 1Proton therapy controls leptomeningeal metastasis, with patients living over twice as long versus conventional radiation.
- 2Randomized phase 2 trial: proton craniospinal therapy offers stability >3x longer for LM compared to standard radiation.
- 3Study funded by PCORI explores LLM-based PainReporter model to summarize cancer patient pain experiences from narrative notes.
- 4Research on tumor genetics and location finds SMAD4 reactivation suppresses liver metastases but increases lung metastases.
- 5Regulatory T cells, via enkephalin, regulate pain/inflammation in skin neuronal circuits.
Why It Matters
Advances in radiotherapeutic options like proton therapy improve outcomes in difficult cancer metastasis scenarios. Testing LLMs for summarising patient pain could impact clinical workflow, interpretation, and the integration of AI into patient care.
Source
EurekAlert
Related News
•EurekAlert
New Framework Compares AI Segmentation Without Ground Truth Annotations
Researchers introduce an open-source approach for evaluating AI anatomy segmentation models in medical imaging without requiring ground truth annotations.
•EurekAlert
AI-Driven Handheld Endomicroscope Enhances Early Cancer Detection
Researchers develop PrecisionView, a handheld AI-powered endomicroscope for real-time, high-resolution cancer diagnostics.
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.